ClinicalTrials.gg
CompletedNCT03484260Updated May 14, 2019

Association Between the Prevalence of Cardiovascular Risk Factors and New Use of Testosterone

An observational study in Hypogonadism, sponsored by Bayer. Completed at 1 site in Germany. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-05-14.

Sponsored by Bayer · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
27,778
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Hypogonadism with a site in Germany — none open to participants now, none under way, none of them phase 3. Hypogonadism · Germany.

Started
2018
the only one that year
Observational
6 of 13
none open now
Registered
13th of 13
by date
Lead sponsor
7 of 13
Bayer

Among the 13 studies in Hypogonadism with a site in Germany, this one is the only one that started in 2018, is one of 6 observational ones, and was the 13th registered.

Hypogonadism

320 studies on the registry are indexed under Hypogonadism; 39 are open to participants now.

Browse Hypogonadism studies →

Open to participants now

None of the 13 studies in Hypogonadism with a site in Germany is open now. The open studies under Hypogonadism, anywhere →

Who these studies take

Of the 24 Hypogonadism studies recruiting now, 9 (38%) set no upper age limit and 12 (50%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Hypogonadism with a site in Germany as a file.
02

Study summary

We will investigate if testosterone is preferentially given to patients at higher risk of cardiovascular events. If this is the case, then observational studies may be prone to selection bias resulting in overestimation of the cardiovascular risk associated with testosterone when compared to a healthier population not taking testosterone

03

Conditions studied

  • Hypogonadism

Browse trials for

Keywords

  • Risk factors predicting the initiation of testosterone use
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The source population is the subset of male patients in the Clinical Practice Research Datalink (CPRD) that has been linked to the Hospital Episodes Statistics (HES) database (CPRD-HES).

Cases will be defined by first testosterone use between 1st January 2001 and 31st March 2016 (study period). The date of the GP consultation associated with the first testosterone prescription will be designated as the index day. All cases will be required to be over 18 years on the index day, to have contributed for at least 2 years to the CPRD-HES link and to have no history of testosterone before the index day.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All male individuals in the source population with a first testosterone use during the study period will be included as cases. The date of the GP consultation associated with the first testosterone prescription will be designated as the index day.

Exclusion criteria

Exclusion Criteria:

  • Patients of less than 18 years on the index day, with less than 2-year contribution to the CPRD-HES link before the index day, or with use of testosterone before the study period will be excluded from the group of cases.
05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
27,778 participants (actual)
Patient registry
No

Groups and cohorts

  • Case group: Testosterone Product

    Male subjects prescribed testosterone in UK

    Drug: Testosterone Product

  • Control group

    Matched male subjects not prescribed testosterone in the UK

Interventions

06

What researchers measure

Primary outcomes

  1. Estimation of the association between cardiovascular risk factors and initiation of testosterone therapy

    Time frame: Retrospectively from 01 January 2001 to 31 March 2016

07

Study locations

1 site
  • Many Locations
    Berlin, 13342, Germany
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in May 2018, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2018
First posted
Mar 30, 2018
StartActual
Apr 1, 2018
Primary completionActual
May 15, 2018
CompletionActual
May 15, 2018
Last update
May 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03484260
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Mar 30, 2018
Start date
Apr 1, 2018
Primary completion
May 15, 2018
Completion
May 15, 2018
Last update
May 14, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion